NCT04701476RecruitingPhase 2
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- First submitted
- 6 Jan 2021
- Start date
- 20 May 2021
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Teclison Ltd.
- Diseases
- Lung cancer, Colorectal cancer
- NCT number
- NCT04701476
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 110
- From 20 May 2021 to the primary completion date, 31 Mar 2027
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior organ transplantation
- Prior autoimmune disorder
Other illness
- Major GI bleeding in the last 2 months
Other
- Liver metastasis more than 50%
- Oxygen saturation less than 92% in room air
- CNS metastasis
Who the study is looking for
- Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
- mCRC progressed on at least two lines of standard chemotherapy; or
- NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
- Measurable disease
- ECOG 0-1
- At least 4 weeks from prior chemotherapy and free from chemo-related toxicity
- Adequate organ function
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| China Medical University Hsinchu Hospital Coordinator of this site? Confirm its status | Hsinchu | Taiwan | Recruiting |
| Chung Shan Medical University Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Recruiting |
| University of California Irvine Medical Center Coordinator of this site? Confirm its status | Orange | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.